Jocelyn Kuryan, MD
Ophthalmology · Southampton, PANPI 1386964989
Payments from drug & device makers
Across 133 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$407
- Tarsus Pharmaceuticals, Inc.$360
- Novartis$312
- Sun Pharmaceutical Industries Inc.$264
- Oyster Point Pharma, Inc.$241
- Alcon$191
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,81199%
- Gifts$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 20 | $407 |
| Tarsus Pharmaceuticals, Inc. | 13 | $360 |
| Novartis | 15 | $312 |
| Sun Pharmaceutical Industries Inc. | 14 | $264 |
| Oyster Point Pharma, Inc. | 14 | $241 |
| Alcon | 10 | $191 |
| AbbVie(2 entities) | 4 | $184 |
| Dompe US, Inc. | 6 | $173 |
| Mallinckrodt Hospital Products Inc. | 5 | $125 |
| Ocular Therapeutix, Inc. | 4 | $82 |
| Harrow Eye, LLC | 4 | $78 |
| Amgen | 4 | $73 |
| Biotissue Holdings Inc. | 3 | $57 |
| Kala Pharmaceuticals, Inc. | 3 | $50 |
| Thea Pharma Inc. | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 2 | $29 |
| Conmed Corporation | 1 | $28 |
| Beaver-visitec International, Inc. | 3 | $26 |
| Organogenesis Inc. | 1 | $25 |
| Sanofi | 1 | $23 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Alimera Sciences, Inc. | 1 | $16 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$125
How this compares
$2,828 in reported general payments places this provider in the 65th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $328,871 |
| RestasisCyclosporine | 99 | $132,817 |
| XiidraLifitegrast | 79 | $98,363 |
| Cyclosporine | 114 | $72,254 |
| XdemvyLotilaner | 14 | $25,416 |
| LumiganBimatoprost | 34 | $18,655 |
| TyrvayaVarenicline Tartrate | 26 | $17,221 |
| RocklatanNetarsudil Mesylat/Latanoprost | 34 | $16,504 |
| Prednisolone Acetate | 298 | $10,985 |
| MieboPerfluorohexyloctane/Pf | 12 | $8,819 |
| Latanoprost | 352 | $5,185 |
| Doxycycline Hyclate | 38 | $4,379 |
| MoxifloxacinMoxifloxacin Hcl | 233 | $3,650 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $2,999 |
| Ketorolac Tromethamine | 207 | $2,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $173 | $328,87112 claims |
| AbbVieRestasis, Lumigan | $184 | $151,471133 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $407 | $107,18291 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $360 | $25,41614 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $241 | $17,22126 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $15 | $16,50434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Southampton
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.